« Back to Record
Citation APA

Galvan, B., Ongena, L., Bruyr, J., Fettweis, G., Lucarelli, E., Lavergne, A., Mariavelle, E., O'Grady, T. M., Hassoun, Z. E. O., Claes, M., Dubois, L., Lee, K. A. W., Kruys, V., Gueydan, C., Durand, J., Hervouet, E., Geyer, F. F., Banito, A., Imle, R., Mao, L., Jayavelu, A. A., Grünewald, T. T., Cidre-Aranaz, F., Twizere, J.-C., & Dequiedt, F. (2025). Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma. Nature communications, 16(1), 6537. doi:10.1038/s41467-025-61725-x


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/392931

Galvan, B., Ongena, L., Bruyr, J., Fettweis, G., Lucarelli, E., Lavergne, A., Mariavelle, E., O'Grady, T. M., Hassoun, Z. E. O., Claes, M., Dubois, L., Lee, K. A. W., Kruys, V., Gueydan, C., Durand, J., Hervouet, E., Geyer, F. F., Banito, A., Imle, R., Mao, L., Jayavelu, A. A., Grünewald, T. T., Cidre-Aranaz, F., Twizere, J.-C., & Dequiedt, F. (2025). Subversion of mRNA degradation pathways by EWSR1::FLI1 represents a therapeutic vulnerability in Ewing sarcoma. Nature communications, 16(1), 6537. doi:10.1038/s41467-025-61725-x